Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

BACKGROUND: Inhibitors of immune checkpoint programmed cell death protein 1 (PD-1) receptor on T cells have shown remarkable clinical outcomes in metastatic melanoma. However, most patients are resistant to therapy. Production of extracellular adenosine, via CD73-mediated catabolism of AMP, contribu...

Descripción completa

Detalles Bibliográficos
Autores principales: Turiello, Roberta, Capone, Mariaelena, Giannarelli, Diana, Morretta, Elva, Monti, Maria Chiara, Madonna, Gabriele, Mallardo, Domenico, Festino, Lucia, Azzaro, Rosa, Levesque, Mitchell P, Imhof, Laurence, Weide, Benjamin, Amaral, Teresa, Chevrier, Marc, Sucker, Antje, Rutkowski, Piotr, Schadendorf, Dirk, Lebbe, Celeste, Luke, Jason John, Wistuba-Hamprecht, Kilian, Dummer, Reinhard, Pinto, Aldo, Morello, Silvana, Ascierto, Paolo A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759961/
https://www.ncbi.nlm.nih.gov/pubmed/33361405
http://dx.doi.org/10.1136/jitc-2020-001689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759961/
https://www.ncbi.nlm.nih.gov/pubmed/33361405
http://dx.doi.org/10.1136/jitc-2020-001689

Ejemplares similares